This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended.  On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

EDX Medical signs agreement to distribute cancer genomic tests from Guardant Health in UK and Nordic countries

EDX Medical Group plc · EDX

5 October 2023

CAMBRIDGE, UK:  EDX Medical Group plc ("EDX Medical, the "Company" or the "Group"), a developer of innovative digital diagnostic products and services for personalised treatment of cancer, heart disease and infectious diseases, today announced that it has entered into a strategic agreement with Guardant Health Inc. (NASDAQ: GH), a leading precision oncology company, to distribute Guardant Health's blood-based liquid biopsy tests in certain market sectors in the U.K. and several Nordic countries.

Under the agreement, EDX Medical will distribute the Guardant360® CDx test for genomic testing in advanced cancer and the Guardant Reveal™ test for residual disease and recurrence detection in early-stage cancer to the private healthcare sector in the U.K. The company will also distribute Guardant360 CDx to public and private sectors in Sweden, Denmark, Norway, Finland and Iceland (Nordics).

The distribution contract with Guardant Health is another step in EDX Medical's strategy to provide healthcare professionals with world-class products and services to rapidly improve cancer diagnosis, drug therapy selection, and recurrence detection, supporting improved clinical outcomes for patients. EDX Medical will provide a local service including optional home-based blood sample collection.

Guardant Health is a market leader in clinical cancer diagnostics and was the first company to receive U.S. Food and Drug Administration (FDA) approval of a blood test for comprehensive genomic profiling of all solid tumors.

Guardant360® CDx is the first FDA-approved blood test for genomic testing, or tumour mutation profiling, across all solid cancers. The test identifies guideline-recommended biomarkers to help oncologists quickly match patients to targeted therapies.

Guardant Reveal™ is the first blood-only liquid biopsy test that detects circulating tumour DNA (ctDNA) for minimal residual disease (MRD) assessment in colorectal, breast, and lung cancer, and can also be used to monitor recurrence in previously diagnosed patients.

"Guardant has proven itself as a true pioneer in cancer genomics and we are proud that they have selected EDX Medical as their commercial partner for the U.K. and Nordic countries," said Professor Sir Chris Evans OBE, founder of EDX Medical. "The tests that we will be distributing are outstanding in the sector and make a tremendous difference to healthcare professionals and patients."

Dr, Mike Hudson, chief executive of EDX Medical, said: "I'm delighted to be working with the scientific leaders at Guardant Health. This agreement provides our clients with access to world-class genomic testing products and the opportunity to join a group of thought leaders in personalised medicine."

"Guardant Health is dedicated to helping cancer patients live longer and healthier lives by providing healthcare professionals with insights into the genomic factors driving tumor growth," said Chris Freeman, Guardant Health chief commercial officer. "We look forward to making blood-based genomic testing available to more physicians and patients across the UK and Europe through our relationship with EDX."

About EDX Medical Group

EDX Medical Group plc develops innovative digital diagnostic products and services, enabling cost effective and timely delivery of personalised treatment for cancer, heart disease and infectious diseases. The company is listed on the AQSE Growth Market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost-effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally.

EDX Medical has established expertise in the design, development, validation and sourcing of diagnostic testing solutions to ISO 13485 and key laboratory tests performed by the Company have been accredited to ISO 15189 by the United Kingdom Accreditation Service (UKAS).

EDX Medical Group operates a molecular biology and diagnostics laboratory in Cambridge, UK, and 100%-owned subsidiary companies, Hutano Diagnostics Limited in Oxford, UK, and Torax Biosciences Ltd in Ireland. 

Learn more: www.edxmedical.co.uk

Contacts: